93 results on '"Oprea-Lager, Daniela E."'
Search Results
2. PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study
3. The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer
4. Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study
5. Biodistribution of 18F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader
6. Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer
7. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma
8. SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
9. The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals
10. Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging
11. Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer
12. Biodistribution of 18F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader.
13. PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
14. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
15. Standardized Uptake Values are Adequate Measures of Lesional 18F‐DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
16. Interobserver agreement in automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim 18F‐FDG PET in DLBCL.
17. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-smallcell lung cancer.
18. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small- cell lung cancer . .
19. Standardized Uptake Values are Adequate Measures of Lesional 18F‐DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
20. Interobserver agreement in automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim 18F‐FDG PET in DLBCL.
21. First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
22. Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer
23. Reply: Quantification of 18F-DCFPyL Uptake: TBR Versus Patlak’s Analysis
24. Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer
25. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone
26. Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
27. The navigating and de-risking role of 89Zr-immuno-PET in the development of biopharmaceuticals.
28. Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
29. Lesion Detection and Interobserver Agreement with Advanced Image-Reconstructions for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
30. Healthy Tissue Uptake of 68Ga‐Prostate Specific Membrane Antigen (PSMA), 18F‐DCFPyL, 18F‐Fluoromethylcholine (FCH) and 18F‐Dihydrotestosterone (FDHT).
31. Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone.
32. PET-Guided Stereotactic Irradiation of Prostate Cancer Lymph Node Metastases
33. Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies
34. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer
35. Quantification of 18F-Fluorocholine Kinetics in Patients with Prostate Cancer
36. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer.
37. Quantification of 18F-Fluorocholine Kinetics in Patients with Prostate Cancer.
38. PET-Guided Stereotactic Irradiation of Prostate Cancer Lymph Node Metastases.
39. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
40. Biodistribution of 18 F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader.
41. Study of 89 Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer.
42. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18 F-FDG PET in Diffuse Large B-Cell Lymphoma.
43. SUVs Are Adequate Measures of Lesional 18 F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
44. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
45. The Role of 89 Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals.
46. Quantification of PD-L1 Expression with 18 F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
47. Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18 F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
48. Reply: Quantification of 18 F-DCFPyL Uptake: TBR Versus Patlak's Analysis.
49. Simplified Methods for Quantification of 18 F-DCFPyL Uptake in Patients with Prostate Cancer.
50. Healthy Tissue Uptake of 68 Ga-Prostate-Specific Membrane Antigen, 18 F-DCFPyL, 18 F-Fluoromethylcholine, and 18 F-Dihydrotestosterone.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.